Tetraphase Pharmaceuticals, Inc.

Miikana Therapeutics, Inc.

Takeda San Diego, Inc.

Affymax Technologies, N.v.

Irori

Discovery Partners International, Inc.

Other

Takeda Pharmaceutical Company Limited

Nexus Biosystems, Inc.

Irori Technologies, Inc.

Xiao-Yi Xiao

Roger B Clark

Louis Plamondon

Dinesh Vinoobhai Patel

Minsheng He

Diana Katharine Hunt

Michael P Nova

Gary S David

Zahra Parandoosh

Cuixiang Sun

Jeffrey Alan Stafford

Andrew E Senyei

Magnus Ronn

John S Ward

Hanan Potash

Chanfeng Zhao

Sheldon Cao

David A Campbell

Jingye Zhou

Magnus Rönn

Robert Zahler

Jason W Brown

Anthony R Gangloff

Phong H Vu

Andrew John Jennings

Jerome C Bressi

Wu-Yan Zhang

Yonghong Deng

Michael Brennan Wallace

Jun Feng

Stephen L Gwaltney

Zhiyuan Zhang

Anthony Treston

Joyce A Sutcliffe

Mark R Bray

Sampath Kumar Anandan

Gregory E Agoston

Chi-Li Chen

Yozo Satoda

Dinish V Patel

Stephen W Kaldor

John E Lillig

Anthony W Czarnik

Trudy Grossman

Gordon W Hudson

Robert Neeper

Anthony M Treston

Joyce Sutcliffe

Robert B Zahler

Magnus P Ronn

Magnus Roenn

Sheldon X Cao

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Tetracycline compounds

Tetracyline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. 

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use. 

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

Polycyclic tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use. 

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

C7-fluoro substituted tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): 

8-AZA tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use. 

In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix with a substrate adapted for attachment and/or synthesis of molecules and an integrally-formed memory device with an optically-encoded identifier to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions then placed within the path of an optical detector adapted to read the optically-encoded identifier and measure biochemical processes on each support matrix. The support matrices may besingulated to be read by the optical detector one at a time.

Multiplexed assay using encoded solid support matrices

Disclosed are protein kinase inhibitors of Formula Ia and Ib, compositions comprising such inhibitors, and methods of use, thereof. More particularly, these compounds and compositions are inhibitors of Aurora-A (Aurora-2) and Aurora-B (Aurora-1) protein kinase. Also disclosed are methods of using these compounds and compositions to prevent and treat diseases associated with protein kinases, especially diseases associated with Aurora-A or Aurora-B, such as cancer. 

Kinase inhibitors

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

Method of treating disease states using substituted pyrazole compounds

Growing community of inventors

San Diego, CA, United States of America

Xiao-Yi Xiao